L26/O-006 Boosting Oocyte Rescue: Nicotinamide Mononucleotide (NMN) Restores the Competence of Poor-Prognosis GV Oocytes in Aged Women
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von C. Rodríguez Varela und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does nicotinamide mononucleotide (NMN) supplementation during germinal vesicle (GV)-rescue improve nuclear, cytoplasmic and genetic competence of aged, poor-prognosis oocytes? Summary answer NMN supplementation increases GV-rescue efficiency in aged women with poor-prognosis, where baseline oocyte rescue performance is low. What is known already Oocyte competence declines over the age of 37. Aging is associated with systemic and oocyte-specific NAD+ depletion, which correlates with reduced oocyte and embryo quality. In aged mice, supplementation with the NAD+ precursor NMN restores oocyte quality and reproductive potential via NAD+ repletion. Thus, we propose the GV-rescue strategy to assess the impact of NMN supplementation on rescued oocyte competence in vitro, stratified by maternal age and oocyte prognosis. Study design, size, duration Experimental, prospective study performed on GVs retrieved from young (19–36y) and aged (37–45y) women undergoing stimulated IVF-cycles at a single infertility clinic (Jan 2024–Nov 2025). GVs were randomized (1:1) to 24h-time-lapse culture in control or NMN-supplemented conditions. To minimize cycle-related bias, two to four GVs per patient were included. Nuclear (Exp. 1), cytoplasmic (Exp.2) and genetic (Exp. 3) competence on rescued oocytes were evaluated. Participants/materials, setting, methods GVs were cultured in CSCM-NXC medium with or without 100 µM NMN (37 °C, 6% CO2, 5% O2). Oocytes reaching metaphase II within 24.3h (rMII) were recorded and the rescue rate (RR=rMII/GV) calculated (Exp.1). rMII then underwent artificial oocyte activation (AOA), and normal activation rate (NOAR=NOA/rMII) was assessed (Exp.2). Activated oocytes exhibiting second polar body extrusion and one pronucleus (NOA) were subsequently analysed for chromosome composition by next-generation sequencing (Exp.3). Paired and χ² tests were applied. Main results and the role of chance A total of 840 GVs (582 from young and 258 from aged women) were allocated to control or NMN-supplemented groups. Overall, the rescue rate (RR) was higher with NMN than in controls (53.1% vs. 44.5%, P = 0.008). In controls, RR differed by age (P = 0.037), whereas no age-related differences were observed in the NMN group (P = 0.252). Based on these results, oocytes were sub-stratified using the mean control RR (44.5%) as threshold, into good- or poor-prognosis exhibiting significant differences in RR (55.0% vs. 30.6%, respectively, P < 0.001), but not in NOA (average: 46.5%, P = 0.300) nor euploidy (average: 45.8%, P = 0.978). In good-prognosis oocytes, RR, NOAR and euploidy rates were comparable between control and NMN groups (RR mean 55.4%, P = 0.854; NOAR mean 47.1%, P = 0.523; euploidy mean 45.9%, P = 0.970), irrespective of age. In poor-prognosis young oocytes, NMN supplementation increases RR (31.8% to 48.6%, P = 0.012), rendered similar NOA (mean 33.3%, P = 0.108), but reduced euploidy (83.3% vs. 25.0%, P = 0.031). In poor-prognosis aged oocytes, NMN supplementation also improved RR (28.8% vs. 50.7%, P = 0.007) without significant changes in NOAR (mean 36.1%, P = 0.452) or euploidy (mean 22.2%, P = 0.518). These results indicate that NMN selectively enhances rescue rates in poor-prognosis oocytes, while its effects on genetic competence vary with age. Limitations, reasons for caution This preliminary analysis requires validation in larger cohorts, particularly for artificial activation and euploidy outcomes. Findings are limited to rMII oocytes obtained via GV-rescue and may not generalize to standard IVF oocytes. Identification of predictive variables for poor-prognosis GV-rescue success is needed before clinical application. Wider implications of the findings NMN supplementation may enhance oocyte competence in aged women with poor-prognosis, improving rescue rates to levels similar to good-prognosis young oocytes. These results support NAD+ repletion as a therapeutic approach to mitigate age-related decline in oocyte quality, highlighting translational potential for improving IVF outcomes in clinical reproductive medicine. Trial registration number No
Zitieren
APA
Varela, C. R., Escrich, L., Pérez, S., Albert, C., Galán, A., Grau, N., Munera, E., Buigues, A., Herraiz, S., & Escribá, M. (2026). L26/O-006 Boosting Oocyte Rescue: Nicotinamide Mononucleotide (NMN) Restores the Competence of Poor-Prognosis GV Oocytes in Aged Women. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.006
Vancouver
Varela CR, Escrich L, Pérez S, Albert C, Galán A, Grau N, et al. L26/O-006 Boosting Oocyte Rescue: Nicotinamide Mononucleotide (NMN) Restores the Competence of Poor-Prognosis GV Oocytes in Aged Women. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.006
BibTeX
@article{Varela2026,
author = {Varela, C. Rodríguez and Escrich, L. and Pérez, S. and Albert, C. and Galán, A. and Grau, N. and Munera, E. and Buigues, A. and Herraiz, S. and Escribá, M.J.},
title = {L26/O-006 Boosting Oocyte Rescue: Nicotinamide Mononucleotide (NMN) Restores the Competence of Poor-Prognosis GV Oocytes in Aged Women},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.006}
}
EUVIMED